Navigating FDA's Future: Janet Woodcock on the Evolving Regulatory Landscape – FDA Watch
Shelly and Wayne chat with Janet Woodcock, M.D., former FDA Principal Deputy Commissioner. Woodcock shares her expert insights on the agency’s approach to navigating the current regulatory environment, the increasing role of artificial intelligence in FDA decision-making, and the future of the agency’s staffing, resources, and regulatory frameworks.
This episode and all future bonus episodes do not include the usual Headlines and Resources Links segments.
About Our Guest
Janet Woodcock, M.D.
Janet Woodcock, now retired, is the former FDA Principal Deputy Commissioner and Center for Drug Evaluation and Research Director. In this role she worked closely with the Commissioner of Food and Drugs to develop and implement key public health initiatives and helped oversee the agency’s day-to-day functions.
She served as the Acting Commissioner of Food and Drugs from Jan. 20, 2021, until Feb. 17, 2022.
Dr. Woodcock began her FDA career in 1986 at the Center for Biologics Evaluation and Research (CBER). At CBER, she served as Director of the Division of Biological Investigational New Drugs and as Acting Deputy Director. She later became Director of CBER’s Office of Therapeutics Research and Review, which oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis during her tenure.
FDA Watch Podcast 